The text starts here.

News Release

FOR IMMEDIATE RELEASE
August 24, 2005

Sanko Junyaku and Eisai Initiate Co-promoting Yamasa Corporation's Diagnostic Kit for Interstitial Pneumonia, SP-D EIA KIT YAMASA

Yamasa Corporation
Sanko Junyaku Co., Ltd.
Eisai Co., Ltd.

It was announced today that Sanko Junyaku Co., Ltd. (Headquarters: Tokyo, President: Masao Jimbo) and Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) will begin to co-promote a diagnostic kit for interstitial pneumonia, SP-D EIA KIT YAMASA (hereinafter referred to as "SP-D"), in Japan on September 1, 2005. The kit was developed and is manufactured and marketed by Yamasa Corporation (Headquarters: Chiba, President: Michio Hamaguchi). Yamasa will continue to be a manufacturer and marketer of this product.

Sanko Junyaku has been manufacturing and marketing its own diagnostic kits for interstitial pneumonia, EITEST(R) KL-6 and PICOLUMI(R) KL-6 (hereinafter referred to as "KL-6"), in co-promotion with Eisai. SP-D and KL-6 with different unique properties are used not only for diagnosis, but also to evaluate disease activity and treatment benefits, and are expected to provide further advantages in identifying disease types and conditions when used in a complementary way.

Yamasa hopes that expanded promotional efforts in partnership with Sanko Junyaku and Eisai will help boost the presence of SP-D in the market and Sanko Junyaku and Eisai will efficiently offer KL-6 together with SP-D, highlighting the features of each.

Through co-promotion of SP-D, the companies aim to intensify the importance of serum markers as diagnostic tools for interstitial pneumonia and provide benefits to patients suffering from the disease.

[The glossary and companies' profiles are attached.]

Contacts:

Yamasa CorporationDiagnostic Dept.03-3668-8558
Sanko Junyaku Co., Ltd.Administrative Dept.
Kazunori Nishina
03-3865-4311
Eisai Co., Ltd.Corporate Communications Dept.03-3817-5120

<Note to the editor>
[Glossary]
  • Interstitial pneumonia

  • Each lung is composed of numerous tiny air sacs called alveoli resembling a bunch of grapes where oxygen is absorbed into the bloodstream. Pneumonia is inflammation in the alveoli, which is classified roughly into two types according to which area is inflamed - interstitial pneumonia which is inflammation in the walls of the alveoli, and alveolar pneumonia, the most typical pneumonia that is inflammation in airways from the bronchi to the alveoli. It is necessary to specify which type of pneumonia a subject is suffering from because patients have to be treated with different therapies depending on the type of disease.

    Idiopathic interstitial pneumonia, a typical type of interstitial pneumonia, is designated as an intractable disease by the Ministry of Health, Labour and Welfare and a research group of the Ministry is currently exploring the pathology of the disease and examining a treatment guideline. As a part of this study project, the group has established diagnostic criteria for idiopathic interstitial pneumonia, which include SP-D and KL-6 in recommended serum markers.


[Profiles of the Involved Companies]
Yamasa Corporation
Representative: Michio Hamaguchi
Location of headquarters: 2-10-1, Araoicho, Choshi, Chiba, Japan
Operations: Manufacturing of soy sauce, various seasonings and pharmaceutical products, and others
Capital : 375 million yen (as of March 31, 2005)

Sanko Junyaku Co., Ltd.
Representative: Masao Jimbo
Location of headquarters:1-10-6, Iwamotocho, Chiyoda-ku, Tokyo, Japan
Operations: Manufacturing, marketing and import of in vitro diagnostics, laboratory reagents, laboratory instruments, etc.
Capital: 5,262 million yen (50.59% owned by Eisai, as of March 31, 2005)

Eisai Co., Ltd.
Representative : Haruo Naito
Location of headquarters: 4-6-10, Koishikawa, Bunkyo-ku, Tokyo, Japan
Operations: Manufacturing, marketing and export of pharmaceuticals, quasi-drugs, etc.
Capital: 44,985 million yen (as of March 31, 2005)